Tesamorelin Results: What the Trials Actually Showed

What Does Tesamorelin Do?

Tesamorelin Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide is a synthetic analog of growth hormone-releasing hormone, the signal your hypothalamus sends to your pituitary gland. Injected subcutaneously once a day, it binds GHRH receptors on the pituitary and prompts it to release your own growth hormone in the same pulsatile rhythm your body already uses. It is not growth hormone. It is the upstream instruction, which is why the feedback loops that normally regulate GH stay intact and why IGF-1 rises within days of starting.

Downstream, elevated growth hormone signaling increases lipolysis, and it does so preferentially in visceral adipose tissue, the fat packed around the organs inside the abdominal wall. That selectivity is the entire story of tesamorelin. It does not suppress appetite, it does not block fat absorption, and it does not melt the pinchable layer under the skin. It mobilizes the specific fat depot most strongly tied to metabolic risk, the one a tape measure only hints at and a scale barely registers.

So the one-sentence answer to "what does tesamorelin do" is this: it raises your own growth hormone output, and over months that shrinks visceral fat while leaving most other tissue alone. The receptor-level detail, the molecule’s Montreal origin story, and the full safety picture live in the complete tesamorelin guide Read nextTesamorelin Peptide: Benefits, Dosage & Visceral FatMost peptides in the compounding space have animal studies and early clinical signals. Tesamorelin has two Phase 3 randomized controlled trials, 816 patients, CT-measured visceral fat data, and an FDA approval. It is a synthetic analog of growth hormone-releasing hormone that triggers your pituitary to produce its own GH in a natural, pulsatile pattern. The result: targeted visceral fat loss without the side effects of injecting growth hormone directly.Read article . This article stays on the question people actually type, which is what happened when it was tested and what you can reasonably expect to notice.

The Trial Results: Real Numbers From 816 Patients

First, the attribution, because it matters. The numbers below come from the clinical program that earned tesamorelin its FDA approval as Egrifta in 2010. Those trials enrolled HIV-positive patients with lipodystrophy, a condition in which antiretroviral therapy drives abnormal visceral fat accumulation. That is the approved indication and the studied population. Compounded tesamorelin prescribed for body composition in people without HIV is off-label use of a different, non-FDA-approved preparation. The trial data is the best evidence anywhere in the GH peptide category, but it describes what happened in that program, not what will happen to you.

With that stated plainly, the numbers are worth taking seriously. The pivotal trial, published by Falutz and colleagues in the New England Journal of Medicine in 2007, randomized 412 patients to 2 mg of tesamorelin or placebo daily for 26 weeks. Visceral adipose tissue measured by CT scan fell 15.2 percent in the tesamorelin group while it rose 5.0 percent on placebo. Triglycerides dropped 50 mg/dL against a 9 mg/dL rise on placebo. The total cholesterol to HDL ratio improved. IGF-1 climbed 81 percent, confirming the pituitary was responding. Glycemic measures showed no significant difference between groups.

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. View study

A second Phase 3 trial of 404 patients, published in 2010, reproduced the finding: visceral fat down 10.9 percent at 26 weeks against 0.6 percent on placebo, with waist circumference and trunk fat improving while limb fat and abdominal subcutaneous fat did not change. Patients who stayed on tesamorelin through the 12-month extension reached a visceral fat reduction of roughly 18 percent. Between the two trials, 816 patients were randomized, which makes this the largest controlled evidence base of any peptide in the PeRx catalog by a wide margin.

Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. View study

Later work extended the picture to the liver. A randomized trial at Massachusetts General Hospital, published in JAMA in 2014, found tesamorelin reduced visceral fat by a net 42 square centimeters versus placebo over six months and modestly reduced liver fat as well, again in HIV-positive patients. Fasting glucose ticked up at two weeks but the difference was no longer significant by six months.

Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. View study

A Realistic Timeline

The single most common mistake with tesamorelin is running it on a BPC-157 Explore PeRxBPC-157The Body Protection CompoundView peptide clock. Injury-repair peptides get judged in weeks. Tesamorelin was designed, dosed, and measured on a six-month horizon, and nothing about the biology speeds that up. Fat mobilization from a specific depot is slow arithmetic: a small daily shift in lipolysis compounding over months. Here is how the sequence typically runs, with the trial-anchored points marked as such.

Why the Scale Barely Moves

Here is the part that disappoints people who skipped the fine print. In trials where visceral fat fell by double-digit percentages, body weight changed little. That is not a contradiction. Visceral fat is a minority share of total body mass, and tesamorelin leaves the biggest depots alone: subcutaneous fat was essentially unchanged across the program, and growth hormone signaling supports lean tissue rather than stripping it. Move a few hundred grams out of one internal compartment while everything else holds and the bathroom scale has nothing to report.

This is why judging tesamorelin by weight is measuring the wrong variable, in both directions. The scale can sit still through a genuine result, and early on it can even drift up slightly with fluid retention while the mechanism is working. The trial designers understood this, which is why the primary endpoint was CT-measured visceral adipose tissue and not a single trial in the program was powered around body weight. If weight loss is the actual goal, tesamorelin is the wrong molecule, and the comparison worth reading is tesamorelin after a GLP-1 Read nextTesamorelin After a GLP-1: Visceral FatPeople finishing a GLP-1 usually ask the same two questions. Will it come back, and will it come back in the worst place? Tesamorelin gets recommended constantly in that conversation, and it is one of the few peptides here with Phase 3 randomized data and an FDA approval behind the molecule. It is also not a weight-loss drug, and the trials that produced its best data were run in a population that is probably not you. Both things are true.Read article , which draws that boundary carefully.

What did track with the visceral change was blood work. Triglycerides fell by about 50 mg/dL in the pivotal trial and the cholesterol-to-HDL ratio improved, which makes a fasting lipid panel a better progress marker than a scale for this particular molecule. Waist circumference improved too, modestly. A shrinking waist at a stable weight is close to a signature pattern for visceral fat loss, and it is exactly the pattern the scale is structurally unable to show you.

What Happens When You Stop

The second Phase 3 trial answered this question directly, and the answer is uncomfortable enough that most articles about tesamorelin results leave it out. At week 26, patients on tesamorelin were re-randomized: some continued, some were switched to placebo without knowing it. The switchers’ visceral fat returned toward baseline over the following months. In the published authors’ own words, the initial improvements were rapidly lost. The continuers held their reductions and extended them.

Mechanistically this is unsurprising. Tesamorelin augments a signal, and when the signal stops, the underlying metabolic conditions that built the visceral depot are still there. The result is maintained by ongoing use, not banked. Anyone weighing a tesamorelin protocol should price that in from the start: the trial-demonstrated result lives inside a window of consistent use, and a plan that ends at month six without any follow-on strategy for diet, training, or continued therapy is a plan to rent the result rather than keep it. This is a conversation to have with the licensed provider who reviews your intake, not a detail to discover at month seven.

The Reddit Version of Results

A large share of the people searching for tesamorelin results end up reading peptide forum threads, because they want something trials do not offer: unfiltered reports from regular people. That instinct is reasonable. It is still worth knowing exactly why forum results and trial results diverge, because the gap is not random.

Start with what the threads get right, because they get real things right. The cost complaints are accurate: tesamorelin is one of the more expensive peptides in any catalog, and a six-month horizon multiplies that. The adherence complaints are accurate: a daily subcutaneous injection for half a year tests anyone’s consistency. The recurring observation that the scale did not move matches the trial data exactly, even when the poster reads it as failure. And the posters who report their midsection refilling after stopping are describing, without knowing it, the same reaccumulation the Phase 3 extension documented.

Now the systematic problems. Nobody posting has serial CT scans, so every reported result is mirror, tape, or scale, the three instruments least suited to the compartment tesamorelin targets. A large fraction of forum tesamorelin is gray-market powder from unverified sources, so a disappointed report may be a report on a vial that contained the wrong dose or nothing at all, a problem a prescribed product from a licensed pharmacy exists to eliminate. Timelines run short: threads are full of verdicts rendered at week six on a molecule measured at week 26. And self-reports select for extremes in both directions, with the quietly satisfied and the quietly indifferent mostly not posting. None of that makes forum readers wrong to look. It means the threads are best read as a record of logistics, side effects, and expectations, and read last, after the trial data, not instead of it.

How to Measure Your Own Results

If you run a tesamorelin protocol, decide before the first injection how you will judge it, because the default instruments will mislead you. A workable measurement stack, roughly in order of usefulness, looks like this.

Waist circumference, done properly. Same time of morning, same landmark at the navel, tape level and snug but not compressing, recorded weekly. Individual readings bounce; the eight-week trend is the signal. This is the cheapest meaningful proxy for the compartment you are targeting. A DEXA scan where available. Many imaging centers offer DEXA body composition scans without a referral for a modest cash price, and newer scanners estimate visceral adipose tissue specifically. One scan at baseline and one near the six-month mark brackets the protocol with actual data. Labs through your physician. A fasting lipid panel tracks the triglyceride effect that moved early in the trials, and IGF-1 confirms the pituitary response the way the trials did. Because tesamorelin raises growth hormone signaling, fasting glucose and HbA1c belong in the panel too, as a safety check as much as a progress marker. Discuss the schedule with your prescribing physician rather than improvising it.

What not to use: daily scale weight, for every reason covered above, and progress photos, which capture the one fat layer tesamorelin does not change. Alongside measurement, the execution details carry weight of their own: consistent daily timing, correct technique from the injection site guide Read nextWhere to Inject Tesamorelin: Sites and RotationTesamorelin is the rare peptide with FDA-approved labeling that tells you exactly where it goes: a subcutaneous injection into the abdomen, rotated. As of July 2026, that approved route is the anchor for how patients use it. Here is the practical site map, the rotation habit that keeps absorption consistent, and the technique details patients ask about after their first vial arrives.Read article , and the dosing structure laid out in the tesamorelin dosage chart Read nextTesamorelin Dosage Chart: Units, Timing, CostTesamorelin dosing numbers found online disagree with each other for a reason: three different Egrifta labels say 2 mg, 1.4 mg, and 1.28 mg, and none of them describe a compounded vial. This page sorts out the three labels, converts milligrams to insulin-syringe units at the 3 mg/mL concentration PeRx ships, and covers timing, cycle length, missed doses, and what a month costs, as of August 31, 2026.Read article . If you are still deciding whether this is the right molecule at all, the comparison pages against AOD-9604 Read nextAOD-9604 vs Tesamorelin: Fat-Loss PeptidesBoth are used for fat loss and body composition, but they work from opposite ends of the growth-hormone system. AOD-9604 is a small fragment of GH that pushes fat cells to release stored fat without raising your growth hormone or IGF-1. Tesamorelin is an FDA-approved GHRH analog that signals your own pituitary to make more GH, and it carries the strongest visceral-fat trial data in the category. Here is the honest comparison.Read article and the other GH peptides Read nextSermorelin vs Ipamorelin vs Tesamorelin: Which Fits?All three raise your own growth hormone, but they pull different levers, last for different amounts of time, and suit different goals. This is a decision guide, not a spec sheet: match the peptide to what you actually want.Read article map the alternatives.

Tesamorelin

Pharmaceutical-grade tesamorelin, prescribed by a licensed provider after an online intake review and dispensed by a licensed US compounding pharmacy. Each vial ships overnight in refrigerated packaging, fully reconstituted and ready to use, with syringes and alcohol swabs included.

The evidence behind the molecule is the strongest in the GH peptide category: two Phase 3 randomized trials with CT-measured visceral fat endpoints and an FDA approval heritage under the brand name Egrifta. $229 per one-month supply.

View Tesamorelin

Common Questions